October 27, 2009 — Women with low- to intermediate-grade ductal carcinoma in situ (DCIS) with margins 3 mm or wider had an "acceptably low rate" of ipsilateral breast events 5 years after excision ...
In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.
Process and Content of Decision Making by Advanced Cancer Patients Entry criteria included DCIS of predominant grade 1 or 2 with a mammographic extent of ≤ 2.5 cm treated with wide excision with final ...
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study A ...
Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
Study findings highlight the importance of follow-up screening and the value of patient communication among DCIS, or ductal carcinoma in situ, survivors. A study published in 2023 sheds light on how ...
SAN ANTONIO ― Oncologists can now offer postmenopausal women with ductal carcinoma in situ (DCIS) two options for prevention of breast cancer recurrence: anastrozole (Arimidex, AstraZeneca ...
DCIS is a pre-invasive breast cancer condition with uncertain progression, often leading to aggressive treatment despite its "stage 0" classification. The lack of definitive guidance for DCIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback